Marlena Fejzo
#63,043
Most Influential Person Now
American medical scientist
Marlena Fejzo's AcademicInfluence.com Rankings
Marlena Fejzobiology Degrees
Biology
#9206
World Rank
#12382
Historical Rank
Genetics
#939
World Rank
#1035
Historical Rank
Download Badge
Biology
Marlena Fejzo's Degrees
- PhD Genetics Stanford University
Why Is Marlena Fejzo Influential?
(Suggest an Edit or Addition)According to Wikipedia, Marlena Schoenberg Fejzo is an American medical scientist and professor of research on hyperemesis gravidarum and ovarian cancer. She received her undergraduate degree from Brown University in Applied Math in 1989 and a Ph.D. in Genetics from Harvard University in 1995. Currently she has joint appointments in the department of Obstetrics and Gynecology at the University of Southern California and the department of Medicine at the University of California, Los Angeles, where she works in the laboratory of Dennis J. Slamon.
Marlena Fejzo's Published Works
Published Works
- Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains (1995) (432)
- Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo (2010) (198)
- Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata (1994) (167)
- Characterization of Genes Encoding Known and Novel Human Mast Cell Tryptases on Chromosome 16p13.3* (1999) (150)
- Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that in lipomas (1996) (126)
- The psychosocial burden of hyperemesis gravidarum (2008) (115)
- Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells (2008) (108)
- Symptoms and pregnancy outcomes associated with extreme weight loss among women with hyperemesis gravidarum. (2009) (102)
- Periostin promotes ovarian cancer angiogenesis and metastasis. (2010) (102)
- Elective pregnancy termination in a large cohort of women with hyperemesis gravidarum. (2007) (93)
- Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer (2005) (92)
- High prevalence of severe nausea and vomiting of pregnancy and hyperemesis gravidarum among relatives of affected individuals. (2008) (92)
- The hD52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma (2000) (90)
- Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum (2018) (82)
- POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. (2014) (79)
- Familial aggregation of hyperemesis gravidarum. (2006) (74)
- Posttraumatic stress symptoms following pregnancy complicated by hyperemesis gravidarum (2011) (72)
- Risk factors, treatments, and outcomes associated with prolonged hyperemesis gravidarum (2012) (64)
- Nausea and vomiting of pregnancy and hyperemesis gravidarum (2019) (59)
- Identification of a YAC spanning the translocation breakpoints in uterine leiomyomata, pulmonary chondroid hamartoma, and lipoma: physical mapping of the 12q14-q15 breakpoint region in uterine leiomyomata. (1995) (57)
- RIN1 is a breast tumor suppressor gene. (2007) (50)
- Secular trends in the treatment of hyperemesis gravidarum. (2008) (49)
- Neurodevelopmental delay in children exposed in utero to hyperemesis gravidarum. (2015) (49)
- Prenatal exposure to hyperemesis gravidarum linked to increased risk of psychological and behavioral disorders in adulthood (2011) (45)
- Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target (2008) (40)
- Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer (2013) (39)
- KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition (2014) (38)
- Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab (2013) (35)
- Antihistamines and other prognostic factors for adverse outcome in hyperemesis gravidarum. (2013) (33)
- Recurrence risk of hyperemesis gravidarum. (2011) (30)
- Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. (2016) (28)
- Genetic analysis of hyperemesis gravidarum reveals association with intracellular calcium release channel (RYR2) (2017) (27)
- Analysis of GDF15 and IGFBP7 in Hyperemesis Gravidarum Support Causality (2019) (26)
- Evidence GDF15 Plays a Role in Familial and Recurrent Hyperemesis Gravidarum (2018) (24)
- Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi (2017) (23)
- Hyperemesis gravidarum: it is time to put an end to the misguided theory of a psychiatric etiology. (2012) (19)
- Psychiatric factors do not affect recurrence risk of hyperemesis gravidarum (2015) (16)
- Analysis of neurodevelopmental delay in children exposed in utero to hyperemesis gravidarum reveals increased reporting of autism spectrum disorder. (2019) (15)
- Change in paternity and recurrence of hyperemesis gravidarum (2012) (15)
- No increased risk of psychological/behavioral disorders in siblings of women with hyperemesis gravidarum (HG) unless their mother had HG (2012) (14)
- Why are Women Still Dying from Nausea and Vomiting of Pregnancy (2016) (11)
- Tissue microarrays from frozen tissues-OCT technique. (2010) (10)
- Patients with a history of hyperemesis gravidarum have similar symptoms during egg stimulation and develop ovarian hyperstimulation syndrome: case series. (2010) (9)
- Analysis of pre- and post-pregnancy issues in women with hyperemesis gravidarum (2017) (8)
- HyperEmesis Level Prediction (HELP Score) Identifies Patients with Indicators of Severe Disease: a Validation Study (2021) (8)
- Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. (2020) (7)
- Whole‐exome sequencing uncovers new variants in GDF15 associated with hyperemesis gravidarum (2022) (6)
- Performance of iPhone Hyperemesis Gravidarum Care App (2019) (5)
- 543: Hyperemesis gravidarum-related hospitalizations and emergency room visits: characterizations and trends, 2000-2009 (2011) (4)
- High Prevalence of Severe Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum Among Relatives of Affected Individuals (2009) (4)
- Intestinal obstruction is a rare complication of ondansetron exposure in hyperemesis gravidarum. (2015) (4)
- Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum (2018) (4)
- Measures of depression and anxiety in women with hyperemesis gravidarum are flawed (2017) (3)
- Hormone receptor genes PGR and GFRAL linked to hyperemesis gravidarum: 905 (2019) (3)
- Patterns of Use and Self-reported Effectiveness of Cannabis for Hyperemesis Gravidarum (2022) (3)
- 768: Exome sequencing in hyperemesis gravidarum reveals association with stress-induced calcium channel (RYR2) (2016) (3)
- A core outcome set for hyperemesis gravidarum studies is a small step in the right direction (2020) (2)
- Long-term health effects in children exposed in utero to hyperemesis gravidarum (2016) (2)
- Psychosocial burden of hyperemesis gravidarum (2006) (2)
- 82: Additional risk variant in GDF15 and a stronger maternal genetic influence linked to Hyperemesis Gravidarum (2020) (1)
- Analysis of GDF 15 and IGFBP 7 in Hyperemesis Gravidarum Support Causality Analyse von GDF-15 und IGFBP-7 bei Hyperemesis gravidarum unterstützt Kausalhypothese (2019) (1)
- Neurodevelopmental delays and in utero exposure to hyperemesis gravidarum (2021) (1)
- The impact of and risk factors for HG : treatment , genetics and epidemiology (2011) (1)
- Genetic Predictors of Ondansetron Effectiveness and Recurrence Risk for Hyperemesis Gravidarum [A177] (2022) (0)
- Response to the questions submitted by Mr. Reichmann. (2016) (0)
- Genetic Approaches Reveal a Non-Hormonal Etiology for Hyperemesis Gravidarum [7L] (2017) (0)
- Critique of inaccurate reporting in Edlavitch article on "Publishing negative findings and the challenge of avoiding type II errors in studies of suspect teratogens: Example of a recent ondansetron publication". (2018) (0)
- Prenatal exposure to hyperemesis gravidarum linked to increased risk of psychological or behavioral disorders (2011) (0)
- 829: Gonadotropin-releasing hormone and luteinizing hormone receptor polymorphisms and risk of hyperemesis gravidarum (2009) (0)
- Inaccuracies in "Long-term health outcomes of children born to mothers with hyperemesis gravidarum: a systematic review and meta-analysis". (2022) (0)
- Abstract 936: KRAS mutational subtypes and copy number variations are predictive of response of human pancreatic cancer cell lines to MEK162in vitro. (2013) (0)
- Symptomatology and outcomes of women with hyperemesis gravidarum as reported in a large registry (2006) (0)
- Association of GDF15-GFRAL-RET Pathway With Hyperemesis Gravidarum Confirmed by Sequencing Families [A163] (2022) (0)
- of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. (2008) (0)
- OBSTETRICS Familial aggregation of hyperemesis gravidarum (2010) (0)
- Nausea and Vomiting of Pregnancy and HG Risk Genes Associated With Blood Levels, Sleep, Stomach Pain, and Other Traits [23N] (2020) (0)
- Author's reply. (2023) (0)
- Pregnant, miserable, and starving in 21st century America (2022) (0)
- Genome-wide association study meta-analysis of hyperemesis gravidarum confirms GDF15 and identifies additional risk loci (2023) (0)
This paper list is powered by the following services:
Other Resources About Marlena Fejzo
What Schools Are Affiliated With Marlena Fejzo?
Marlena Fejzo is affiliated with the following schools: